Viridian Therapeutics, Inc.
VRDN
Jodie situation report
Viridian Therapeutics, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 10 of 16 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.
- At least 11 of 16 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as NBIX begins moving with the group.
Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.
Who this business touches
The relationships behind VRDN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ZBIOZenas BioPharma, Inc.partnerMay 5, 2026 ▾
“In May 2022, we entered into a manufacturing development and supply agreement with Zenas BioPharma to manufacture and supply, or have manufactured and supplied, clinical drug product for development purposes.”
HTGCHercules Capital, Inc.lenderMay 5, 2026 ▾
“Interest expense consists of cash and non-cash interest expense related to our DRI Purchase and Sale Agreement and Hercules Loan and Security Agreement.”
Depended on by
ZBIOZenas BioPharma, Inc.partnerMar 16, 2026 ▾
“Partnered Regional Programs We also have in-licensed the development and commercialization rights to ZB001 (also known as VRDN-001), an IGF-1R monoclonal antibody, and related programs from Viridian Therapeutics, Inc.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
VRDN is currently a Participant in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.